Replies to post #2512 on Bio Path Holdings Inc (BPTH)

[Gpheart2016]

Once again, it looks like we cannot break through the .95 level. I do not see a way to avoid delisting from Nasdaq. The only pending news that could help is result of the first 19 patients in the AML trial. That is not likely to happen before end of 2017. Further dilution of shares will be necessary before then.
Does anyone expect a bump in stock price when phase 1/b CML study begins or IND for BP 1002 is successful?

[iloveu2]

This is going to get ugly!